Rhumbline Advisers Bolt Biotherapeutics, Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.41 - $2.91 $33,347 - $68,824	-23,651 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.74 - $4.82 $6,562 - $11,543	2,395 Added 11.27%	23,651 $65,000
Q4 2021 Feb 10, 2022	SELL	$4.19 - $13.97 $833 - $2,780	-199 Reduced 0.93%	21,256 $104,000
Q3 2021 Nov 12, 2021	BUY	$11.15 - $18.6 $92,054 - $153,561	8,256 Added 62.55%	21,455 $271,000
Q2 2021 Aug 05, 2021	BUY	$15.4 - $31.46 $37,191 - $75,975	2,415 Added 22.39%	13,199 $204,000
Q1 2021 May 06, 2021	BUY	$25.86 - $39.93 $278,874 - $430,605	10,784 New	10,784 $355,000

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $21.8M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.